全文获取类型
收费全文 | 40740篇 |
免费 | 3607篇 |
国内免费 | 1171篇 |
专业分类
耳鼻咽喉 | 104篇 |
儿科学 | 1258篇 |
妇产科学 | 193篇 |
基础医学 | 2491篇 |
口腔科学 | 60篇 |
临床医学 | 5742篇 |
内科学 | 12807篇 |
皮肤病学 | 129篇 |
神经病学 | 343篇 |
特种医学 | 2106篇 |
外国民族医学 | 8篇 |
外科学 | 2992篇 |
综合类 | 8520篇 |
现状与发展 | 2篇 |
预防医学 | 1980篇 |
眼科学 | 28篇 |
药学 | 3876篇 |
43篇 | |
中国医学 | 1826篇 |
肿瘤学 | 1010篇 |
出版年
2024年 | 54篇 |
2023年 | 680篇 |
2022年 | 1023篇 |
2021年 | 1800篇 |
2020年 | 1987篇 |
2019年 | 1692篇 |
2018年 | 1656篇 |
2017年 | 1745篇 |
2016年 | 1825篇 |
2015年 | 1757篇 |
2014年 | 3144篇 |
2013年 | 3305篇 |
2012年 | 2649篇 |
2011年 | 2708篇 |
2010年 | 2192篇 |
2009年 | 1915篇 |
2008年 | 1820篇 |
2007年 | 1816篇 |
2006年 | 1631篇 |
2005年 | 1430篇 |
2004年 | 1157篇 |
2003年 | 1014篇 |
2002年 | 807篇 |
2001年 | 731篇 |
2000年 | 604篇 |
1999年 | 517篇 |
1998年 | 395篇 |
1997年 | 374篇 |
1996年 | 373篇 |
1995年 | 367篇 |
1994年 | 326篇 |
1993年 | 250篇 |
1992年 | 245篇 |
1991年 | 198篇 |
1990年 | 198篇 |
1989年 | 148篇 |
1988年 | 137篇 |
1987年 | 121篇 |
1986年 | 111篇 |
1985年 | 143篇 |
1984年 | 110篇 |
1983年 | 57篇 |
1982年 | 57篇 |
1981年 | 54篇 |
1980年 | 48篇 |
1979年 | 34篇 |
1978年 | 25篇 |
1977年 | 25篇 |
1976年 | 22篇 |
1975年 | 14篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
目的 探讨不同时期慢性阻塞性肺疾病(COPD)患者血清诱饵受体3(DcR3)、凋亡抑制蛋白(Survivin)表达水平及临床意义。方法 选取2018年9月—2019年12月本院收治的92名COPD患者为研究对象,其中稳定型COPD 50例,急性加重期COPD 42例;同期本院健康体检者88例为对照组。测定各组研究对象血清DcR3、Survivin水平及肺功能指标。 与对照组[DcR3(106.54±48.35)pg/mL,Survivin(98.85±26.59)pg/mL]比较,稳定期组和急性加重期组血清DcR3[(395.23±123.85)pg/mL,(1 248.81±213.59)pg/mL]、Survivin [(267.54±84.69)pg/mL,(1 233.95±307.26)pg/mL]水平升高;与稳定期组比较,急性加重期组血清DcR3、Survivin水平升高。与对照组比较,稳定期组和急性加重期组FEV1%、FEV1 /FVC、DLCO%水平降低(P<0.001);与稳定期组比较,急性加重期组FEV1%、FEV1 /FVC、DLCO%水平降低(P<0.001)。随着低氧血症严重程度的增加,COPD患者血清DcR3、Survivin水平逐渐增加(P<0.001)。多因素logistics回归分析显示,高水平DcR3、Survivin、IL-12、hs-CRP为COPD病情的危险因素(P<0.001)。DcR3、Survivin与FEV、FEV1 /FVC呈负相关,与IL-12、TNF-α、hs-CRP呈正相关(P<0.001)。 COPD稳定期、急性加重期患者血清DcR3、Survivin表达水平升高,且DcR3、Survivin与COPD病情严重程度呈正相关。 相似文献
2.
目的 通过分析特发性肺纤维化急性加重期(AE-IPF)患者证候与血清生物标志物的关系,为中医辨证治疗提供参考。方法 采用观察性研究设计,收集2019年3月至2019年11月三个中心的AE-IPF患者76例,其中痰热壅肺证26例、痰浊阻肺证50例,并纳入健康志愿者10例作为对照。采用ELISA测定患者血清CCL18、HMGB1、KL-6、MMP-7、SP-A和SP-D水平,分析与中医证候的相关性。结果 AE-IPF患者血清CCL18、HMGB1、KL-6、MMP-7、SP-A和SP-D水平均显著高于健康对照组。血清CCL18、HMGB1、KL-6、MMP-7和SP-D水平在痰热壅肺证和痰浊阻肺证患者间无显著性差异(P>0.05),而血清SP-A水平存在显著性差异(P<0.05)。结论 血清SP-A与AE-IPF证候存在一定的相关性,血清SP-A的浓度升高,与痰热壅肺证关系越密切,反之,血清SP-A浓度降低,则与痰浊阻肺证关系越密切。AE-IPF痰热壅肺证患者的预后可能较痰浊阻肺证患者更差。 相似文献
3.
《Journal of the American College of Radiology》2022,19(3):407-414
ObjectiveTo evaluate the impact of structured recommendations on follow-up completion for incidental lung nodules (ILNs).MethodsPatients with ILNs before and after implementation of structured Fleischner recommendations and electronic tracking were sampled randomly. The cohorts were compared for imaging follow-up. Multivariable logistic regression was used to assess appropriate follow-up and loss to follow-up, with independent variables including use of structured recommendations or tracking, age, sex, race, ethnicity, setting of the index test (inpatient, outpatient, emergency department), smoking history, and nodule features.ResultsIn all, 1,301 patients met final inclusion criteria, including 255 patients before and 1,046 patients after structured recommendations or tracking. Baseline differences were found in the pre- and postintervention groups, with smaller ILNs and younger age after implementing structured recommendations. Comparing pre- versus postintervention outcomes, 40.0% (100 of 250) versus 29.5% (309 of 1,046) of patients had no follow-up despite Fleischner indications for imaging (P = .002), and among the remaining patients, 56.6% (82 of 145) versus 75.0% (553 of 737) followed up on time (P < .001). Delayed follow-up was more frequent before intervention. Differences postintervention were mostly accounted for by nodules ≤8 mm in the outpatient setting (P < .001). In multivariable analysis, younger age, White race, outpatient setting, and larger nodule size showed significant association with appropriate follow-up completion (P < .015), but structured recommendations did not. Similar results applied for loss to follow-up.DiscussionConsistent use of structured reporting is likely key to mitigate selection bias when benchmarking rates of appropriate follow-up of ILN. Emergency department patients and inpatients are at high risk of missed or delayed follow-up despite structured recommendations. 相似文献
4.
目的 对中医药治疗特发性肺纤维化(idiopathic pulmonary fibrosis, IPF)的系统评价(SRs)进行再评价。方法 检索知网、中国生物医学数据库、维普、万方、The Cochrane Library、Web of Science、PubMed和EMbase数据库,纳入中医药治疗IPF的SRs,截止2021年5月。使用AMSTAR 2量表进行方法学质量评价,GRADE系统工具进行结局指标证据质量分级。结果 共纳入28篇文献,试验组除辨证论治外,治疗方法集中在活血化瘀、补肺益气等方面,基本符合治疗法则。结果显示中医药治疗IPF可以提高有效率、增加肺功能、提高PaO2、增加6WMD、缓解临床症状、提高患者的生活质量等。AMSTAR 2量表评价,所纳入SRs均有多项关键条目不达标,整体方法学质量等级不高。采用GRADE工具进行质量分级,一共234个结局指标,无高等证据质量,整体证据等级不高。结论 中医药对比西医治疗IPF有效且不良反应不明显,但RCT研究和系统评价研究方法质量尚有缺陷,完全按照西医评价指标可能会低估真实结果,未来需要更规范的研究及适合中医的评价指标,对中医药研究的安全性方面关注还有待提高。 相似文献
5.
6.
7.
8.
Thomas Fuchs-Buder Sorin J. Brull Malin Jonsson Fagerlund J. Ross Renew Guy Cammu Glenn S. Murphy Michiel Warlé Matias Vested Béla Fülesdi Reka Nemes Malachy O. Columb Daniela Damian Peter J. Davis Hajime Iwasaki Lars I. Eriksson 《Acta anaesthesiologica Scandinavica》2023,67(8):994-1017
The set of guidelines for good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents was developed following an international consensus conference in Copenhagen in 1996 (Viby-Mogensen et al., Acta Anaesthesiol Scand 1996, 40 , 59–74); the guidelines were later revised and updated following the second consensus conference in Stockholm in 2005 (Fuchs-Buder et al., Acta Anaesthesiol Scand 2007, 51 , 789–808). In view of new devices and further development of monitoring technologies that emerged since then, (e.g., electromyography, three-dimensional acceleromyography, kinemyography) as well as novel compounds (e.g., sugammadex) a review and update of these recommendations became necessary. The intent of these revised guidelines is to continue to help clinical researchers to conduct high-quality work and advance the field by enhancing the standards, consistency, and comparability of clinical studies. There is growing awareness of the importance of consensus-based reporting standards in clinical trials and observational studies. Such global initiatives are necessary in order to minimize heterogeneous and inadequate data reporting and to improve clarity and comparability between different studies and study cohorts. Variations in definitions of endpoints or outcome variables can introduce confusion and difficulties in interpretation of data, but more importantly, it may preclude building of an adequate body of evidence to achieve reliable conclusions and recommendations. Clinical research in neuromuscular pharmacology and physiology is no exception. 相似文献
9.
儿童哮喘与慢性阻塞性肺疾病(COPD)是儿童期与成人期常见的存在气流受限的慢性气道疾病。研究发现,儿童哮喘会增加成年期罹患COPD的风险,而肺功能变化是预测COPD患病风险的重要指标。针对哮喘患儿建立长期肺功能监测管理,对于评估其成年后存在不可逆气道阻塞的风险有重要意义。文章综述儿童哮喘与COPD相关的研究进展。 相似文献
10.
The purpose of this review is to describe the current state of the art in clinical imaging for NICU patients, divided into major areas that correspond to likely phenotypes of neonatal respiratory disease: airway abnormalities, parenchymal disease, and pulmonary vascular disease. All common imaging modalities (ultrasound, X-ray, CT, and MRI) are discussed, with an emphasis on modalities that are most relevant to the individual underlying aspects of disease. Some promising aspects of dynamic and functional imaging are included, where there may be future clinical applicability. 相似文献